Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables

Psychiatry Research

Volumn 206, Issue 2-3, 2013, Pages 181-187

  Díaz, Ignacio ^a   Pelayo Terán, Jose María ^b,c   Pérez Iglesias, Rocío ^b,c   Mata, Ignacio ^b,c   Tabarés Seisdedos, Rafael ^c,d   Suárez Pinilla, Paula ^b   Vázquez Barquero, José Luis ^b,c   Crespo Facorro, Benedicto ^b,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Clinical practice; Duration of untreated psychosis (DUP); Negative symptoms; Premorbid adjustment; Prognosis; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; PROGNOSIS; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME TO TREATMENT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EDUCATIONAL STATUS; FEMALE; HALOPERIDOL; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; PROGNOSIS; PSYCHOTIC DISORDERS; REMISSION INDUCTION; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TIME-TO-TREATMENT; YOUNG ADULT;

MLCS; MLOWN;

EID: 85027923388     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.10.011     Document Type: Article

References (47)

1. Addington, J., Addington, D., Symptom remission in first episode patients. Schizophrenia Research 106 (2008), 281–285.
2. Andreasen, N.C., Carpenter, W.T. Jr., Kane, J.M., Lasser, R.A., Marder, S.R., Weinberger, D.R., Remission in schizophrenia: proposed criteria and rationale for consensus. The American Journal of Psychiatry 162 (2005), 441–449.
3. Andreasen, N.C., Scale for Assessment of Negative Symptoms. 1983, University of Iowa, Iowa City, IO.
4. Andreasen, N.C., Scale for Assessment of Positive Symptoms. 1984, University of Iowa, Iowa City, IO.
5. Bachmann, S., Bottmer, C., Schroder, J., One-year outcome and its prediction in first-episode schizophrenia—a naturalistic study. Psychopathology 41 (2008), 115–123.
6. Boter, H., Peuskens, J., Libiger, J., Fleischhacker, W.W., Davidson, M., Galderisi, S., Kahn, R.S., Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research 115 (2009), 97–103.
7. Cassidy, C.M., Norman, R., Manchanda, R., Schmitz, N., Malla, A., Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophrenia Bulletin 36 (2010), 1001–1008.
8. Caton, C.L., Hasin, D.S., Shrout, P.E., Drake, R.E., Dominguez, B., Samet, S., Schanzer, B., Predictors of psychosis remission in psychotic disorders that co-occur with substance use. Schizophrenia Bulletin 32 (2006), 618–625.
9. Ciudad, A., Alvarez, E., Bobes, J., San, L., Polavieja, P., Gilaberte, I., Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophrenia Research 108 (2009), 214–222.
10. Correll, C.U., Malhotra, A.K., Kauskhik, S., McMeniman, M., Kane, J.M., Early prediction of antipsychotic response in schizophrenia. The American Journal of Psychiatry 160 (2003), 2063–2065.
11. Craig, T.J., Bromet, E.J., Fennig, S., Tanenberg-Karant, M., Lavelle, J., Galambos, N., Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?. The American Journal of Psychiatry 157 (2000), 60–66.
12. Crespo-Facorro, B., Perez-Iglesias, R., Mata, I., Caseiro, O., Martínez-Garcia, O., Pardo, G., Ramirez-Bonilla, M., Pelayo-Terán, J.M., Vázquez-Barquero, J.L., Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. Journal of Psychiatric Research 45 (2011), 763–769.
13. Crespo-Facorro, B., Pelayo-Terán, J.M., Perez-Iglesias, R., Ramirez-Bonilla, M., Martínez-García, O., Pardo-García, G., Vázquez-Barquero, J.L., Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research 41 (2007), 659–666.
14. Crespo-Facorro, B., Perez-Iglesias, R., Ramirez-Bonilla, M., Martínez-García, O., Llorca, J., Vázquez-Barquero, J.L., A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. The Journal of Clinical Psychiatry 67 (2006), 1511–1521.
15. Emsley, R., Rabinowitz, J., Medori, R., Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophrenia Research 89 (2007), 129–139.
16. Flyckt, L., Mattsson, M., Edman, G., Carlsson, R., Cullberg, J., Predicting 5-year outcome in first-episode psychosis: construction of a prognostic rating scale. The Journal of Clinical Psychiatry 67 (2006), 916–924.
17. González-Blanch, C., Crespo-Facorro, B., Alvarez-Jiménez, M., Rodríguez-Sánchez, J.M., Pelayo-Terán, J.M., Pérez-Iglesias, R., Vázquez-Barquero, J.L., Cognitive dimensions in first-episode schizophrenia spectrum disorders. Journal of Psychiatric Research 41 (2007), 968–977.
18. Harrison, G., Hopper, K., Craig, T., Laska, E., Siegel, C., Wanderling, J., Dube, K.C., Ganev, K., Giel, R., an der Heiden, W., Holmberg, S.K., Janca, A., Lee, P.W., León, C.A., Malhotra, S., Marsella, A.J., Nakane, Y., Sartorius, N., Shen, Y., Skoda, C., Thara, R., Tsirkin, S.J., Varma, V.K., Walsh, D., Wiersma, D., Recovery from psychotic illness: a 15- and 25-year international follow-up study. The British Journal of Psychiatry 178 (2001), 506–517.
19. Harvey, P.D., Bellack, A.S., Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?. Schizophrenia Bulletin 35 (2009), 300–306.
20. Ho, B.C., Andreasen, N.C., Flaum, M., Nopoulos, P., Miller, D., Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. The American Journal of Psychiatry 157 (2000), 808–815.
21. Janca, A., Kastrup, M., Katschnig, H., López-Ibor, J.J., Mezzich, J.E., Sartorius, N., The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Social Psychiatry and Psychiatric Epidemiology 31 (1996), 349–354.
22. Keefe, R.S., Fenton, W.S., How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophrenia Bulletin 33 (2007), 912–920.
23. Lambert, M., Karow, A., Leucht, S., Schimmelmann, B.G., Naber, D., Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues in Clinical Neuroscience 12 (2010), 393–407.
24. Lambert, M., Naber, D., Schacht, A., Wagner, T., Hundemer, H.P., Karow, A., Huber, C.G., Suarez, D., Haro, J.M., Novick, D., Dittmann, R.W., Schimmelmann, B.G., Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatrica Scandinavica 118 (2008), 220–229.
25. Lasser, R.A., Nasrallah, H., Helldin, L., Peuskens, J., Kane, J., Docherty, J., Tronco, A.T., Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophrenia Research 96 (2007), 223–231.
26. Lieberman, J.A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., Hamer, R.M., Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology 28 (2003), 995–1003.
27. Lingjarge, O., Ahlfors, U.G., Bech, P., Dencker, S.J., Elgen, K., The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Sacandinavica(Suppl. 334), 1987, 1–100.
28. Malla, A., Norman, R., Schmitz, N., Manchanda, R., Bechard-Evans, L., Takhar, J., Harricharan, R., Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychological Medicine 36 (2006), 649–658.
29. Malla, A.K., Norman, R.M., Manchanda, R., Ahmed, M.R., Scholten, D., Harricharan, R., Cortese, L., Takhar, J., One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophrenia Research 54 (2002), 231–242.
30. Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., Croudace, T., Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry 62 (2005), 975–983.
31. Novick, D., Haro, J.M., Suarez, D., Vieta, E., Naber, D., Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophrenia Research 108 (2009), 223–230.
32. Overall, J.E., Gorham, D.R., The brief psychiatric rating scale. Psychological Reports 10 (1962), 799–812.
33. Pelayo-Teran, J.M., Perez-Iglesias, R., Ramirez-Bonilla, M., González-Blanch, C., Martínez-García, O., Pardo-García, G., Rodríguez-Sánchez, J.M., Roiz-Santiáñez, R., Tordesillas-Gutiérrez, D., Mata, I., Vázquez-Barquero, J.L., Crespo-Facorro, B., Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Intervention in Psychiatry 2 (2008), 178–187.
34. Perkins, D., Lieberman, J., Gu, H., Tohen, M., McEvoy, J., Green, A., Zipursky, R., Strakowski, S., Sharma, T., Kahn, R., Gur, R., Tollefson, G., Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. The British Journal of Psychiatry 185 (2004), 18–24.
35. Perkins, D.O., Gu, H., Boteva, K., Lieberman, J.A., Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. The American Journal of Psychiatry 162 (2005), 1785–1804.
36. Petersen, L., Thorup, A., Oqhlenschlaeger, J., Christensen, T.Ø., Jeppesen, P., Krarup, G., Jørrgensen, P., Mortensen, E.L., Nordentoft, M., Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. The Canadian Journal of Psychiatry 53 (2008), 660–670.
37. Reichenberg, A., Harvey, P.D., Bowie, C.R., Mojtabai, R., Rabinowitz, J., Heaton, R.K., Bromet, E., Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophrenia Bulletin 35 (2008), 1022–1029.
38. Schennach-Wolff, R., Jager, M., Mayr, A., Meyer, S., Kühn, K.U., Klingberg, S., Heuser, I., Klosterkötter, J., Gastpar, M., Schmitt, A., Schlösser, R., Schneider, F., Gaebel, W., Seemüller, F., Möller, H.J., Riedel, M., Predictors of response and remission in the acute treatment of first-episode schizophrenia patients—is it all about early response?. European Neuropsychopharmacology 21 (2011), 370–378.
39. Schennach-Wolff, R., Seemuller, F., Obermeier, M., Messer, T., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L.G., Gaebel, W., Klosterkötter, J., Heuser, I., Maier, W., Lemke, M.R., Rüther, E., Buchkremer, G., Gastpar, M., Jäger, M., Möller, H.J., Riedel, M., Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders. European Psychiatry 26 (2011), 284–292.
40. Schuepbach, D., Hill, S.K., Sanders, R.D., Hell, D., Keshavan, M.S., Sweeney, J.A., Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: a 2-year followup. Schizophrenia Bulletin 30 (2004), 837–848.
41. Simonsen, E., Friis, S., Haahr, U., Johannessen, J.O., Larsen, T.K., Melle, I., Opjordsmoen, S., Rund, B.R., Vaglum, P., McGlashan, T., Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatrica Scandinavica 116 (2007), 54–61.
42. Ucok, A., Serbest, S., Kandemir, P.E., Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Research 189 (2011), 33–37.
43. van Mastrigt, S., Addington, J., Assessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale. Journal of Psychiatry and Neuroscience 27 (2002), 92–101.
44. van Os, J., Burns, T., Cavallaro, R., Leucht, S., Peuskens, J., Helldin, L., Bernardo, M., Arango, C., Fleischhacker, W., Lachaux, B., Kane, J.M., Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica 113 (2006), 91–95.
45. van Os, J., Drukker, M., à Campo, J., Meijer, J., Bak, M., Delespaul, P., Validation of remission criteria for schizophrenia. The American Journal of Psychiatry 163 (2006), 2000–2002.
46. Walshe, M., Taylor, M., Schulze, K., Bramon, E., Frangou, S., Stahl, D., Kravariti, E., Daly, E., Fearon, P., Murray, R.M., McDonald, C., Familial liability to schizophrenia and premorbid adjustment. The British Journal of Psychiatry 191 (2007), 260–261.
47. Wunderink, L., Nienhuis, F.J., Sytema, S., Wiersma, D., Predictive validity of proposed remission criteria in first episode schizophrenic patients responding to antipsychotics. Schizophrenia Bulletin 33 (2007), 792–796.